These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1846868)

  • 41. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a).
    de Kraker AT; Kenemans P; Smolders RG; Kroeks MV; van der Mooren MJ
    Maturitas; 2004 Nov; 49(3):253-63. PubMed ID: 15488354
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
    Freeman EW; Sondheimer SJ; Rickels K
    Psychopharmacol Bull; 1997; 33(2):303-9. PubMed ID: 9230648
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Postmenopausal hormone therapy and change in mammographic density.
    Greendale GA; Reboussin BA; Slone S; Wasilauskas C; Pike MC; Ursin G
    J Natl Cancer Inst; 2003 Jan; 95(1):30-7. PubMed ID: 12509398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis.
    Adams MR; Register TC; Golden DL; Wagner JD; Williams JK
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):217-21. PubMed ID: 9012659
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy.
    Kalyan S; Hitchcock CL; Sirrs S; Pudek M; Prior JC
    Pharmacotherapy; 2010 May; 30(5):442-52. PubMed ID: 20411996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial.
    Carr BR; Marshburn PB; Weatherall PT; Bradshaw KD; Breslau NA; Byrd W; Roark M; Steinkampf MP
    J Clin Endocrinol Metab; 1993 May; 76(5):1217-23. PubMed ID: 8496313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Studies on endocrine therapy of endometriosis].
    Terakawa N
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Aug; 41(8):981-9; discussion 1000-7. PubMed ID: 2530291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects on bone of oral hormone replacement therapy initiated 2 years after ovariectomy in young adult monkeys.
    Jayo MJ; Register TC; Carlson CS
    Bone; 1998 Oct; 23(4):361-6. PubMed ID: 9763148
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS).
    Dhar V; Murphy BE
    Psychoneuroendocrinology; 1990; 15(5-6):489-93. PubMed ID: 1966304
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular effects of synthetic or natural progestagen combined with conjugated equine estrogen in healthy postmenopausal women.
    Koh KK; Jin DK; Yang SH; Lee SK; Hwang HY; Kang MH; Kim W; Kim DS; Choi IS; Shin EK
    Circulation; 2001 Apr; 103(15):1961-6. PubMed ID: 11306524
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen.
    Wakatsuki A; Okatani Y; Ikenoue N; Fukaya T
    Circulation; 2002 Mar; 105(12):1436-9. PubMed ID: 11914251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
    Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women.
    Sherwin BB
    J Clin Endocrinol Metab; 1991 Feb; 72(2):336-43. PubMed ID: 1846872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
    Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM
    J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women.
    de Kleijn MJ; Wilmink HW; Bots ML; Bak AA; van der Schouw YT; Planellas J; Engelen S; Banga JD; Grobbee DE
    Atherosclerosis; 2001 Dec; 159(2):357-65. PubMed ID: 11730815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.
    Spicer DV; Pike MC; Pike A; Rude R; Shoupe D; Richardson J
    Contraception; 1993 May; 47(5):427-44. PubMed ID: 8390340
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
    Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
    Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of the estrogen and progestin in hormonal replacement therapy on apolipoprotein A-I kinetics in postmenopausal women.
    Lamon-Fava S; Postfai B; Diffenderfer M; DeLuca C; O'Connor J; Welty FK; Dolnikowski GG; Barrett PH; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2006 Feb; 26(2):385-91. PubMed ID: 16339502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: a 2-year prospective study.
    Mizunuma H; Okano H; Soda M; Kagami I; Miyamoto S; Tokizawa T; Honjo S; Ibuki Y
    Maturitas; 1997 May; 27(1):69-76. PubMed ID: 9158080
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of ovulation with oral progestins--effectiveness in premenstrual syndrome.
    West CP
    Eur J Obstet Gynecol Reprod Biol; 1990; 34(1-2):119-28. PubMed ID: 2303145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.